Bispecific antibodies for the treatment of neuroblastoma. Review uri icon

Overview

abstract

  • Bispecific antibodies (BsAb) are a new generation of antibody-based therapy, conveying artificial specificity to polyclonal T cells or radiohaptens. These drugs have been successfully implemented to cure hematologic malignancies and are under clinical investigation for solid tumors including HRNB. BsAbs designed to engage T cells or increase the therapeutic index of radiotherapy hold the potential to significantly improve the long-term survival of HRNB patients by shrinking bulky tumors and more effectively eliminating micrometastases and preventing relapse. BsAbs can also be used to arm T cells, yielding a product analogous to CAR T cells, possibly with an improved safety profile. A thoughtful and realistic integration of these therapies into the standard of care should benefit more patients worldwide. Here we describe the history of development of BsAbs for HRNB, which dates back almost three decades. We discuss the merits and pitfalls of all relevant BsAbs, including T cell-engagers and agents used for radioimmunotherapy, highlighting the importance of structural design and interdomain spacing for anti-tumor efficacy.

publication date

  • July 10, 2022

Research

keywords

  • Antibodies, Bispecific
  • Neuroblastoma

Identity

Scopus Document Identifier

  • 85135132489

Digital Object Identifier (DOI)

  • 10.1016/j.pharmthera.2022.108241

PubMed ID

  • 35830901

Additional Document Info

volume

  • 237